ValuEngine upgraded shares of Heron Therapeutics (NASDAQ:HRTX) from a hold rating to a buy rating in a research note released on Monday morning.
Several other research analysts have also recently issued reports on the company. Mizuho reiterated a buy rating and issued a $28.00 price objective on shares of Heron Therapeutics in a research report on Friday, December 8th. Cantor Fitzgerald set a $31.00 price objective on Heron Therapeutics and gave the stock a buy rating in a research report on Monday, January 15th. BidaskClub upgraded Heron Therapeutics from a hold rating to a buy rating in a research report on Saturday, January 20th. Oppenheimer set a $27.00 price objective on Heron Therapeutics and gave the stock a buy rating in a research report on Thursday, December 14th. Finally, Zacks Investment Research cut Heron Therapeutics from a buy rating to a hold rating in a research report on Wednesday, January 10th. One investment analyst has rated the stock with a hold rating and fourteen have given a buy rating to the company. Heron Therapeutics has a consensus rating of Buy and a consensus target price of $35.92.
NASDAQ:HRTX opened at $27.90 on Monday. Heron Therapeutics has a 1 year low of $12.70 and a 1 year high of $32.70.
In other news, Director Kevin C. Tang bought 192,308 shares of the stock in a transaction on Thursday, March 29th. The shares were bought at an average price of $26.00 per share, with a total value of $5,000,008.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Barry D. Quart sold 100,000 shares of the company’s stock in a transaction on Wednesday, March 14th. The shares were sold at an average price of $24.75, for a total value of $2,475,000.00. Following the completion of the sale, the chief executive officer now directly owns 167,993 shares in the company, valued at approximately $4,157,826.75. The disclosure for this sale can be found here. Insiders sold 225,584 shares of company stock worth $6,141,680 in the last three months. 19.93% of the stock is owned by corporate insiders.
A number of institutional investors have recently bought and sold shares of the business. Geode Capital Management LLC grew its holdings in Heron Therapeutics by 0.6% in the fourth quarter. Geode Capital Management LLC now owns 397,456 shares of the biotechnology company’s stock valued at $7,193,000 after purchasing an additional 2,410 shares during the last quarter. Fox Run Management L.L.C. boosted its stake in shares of Heron Therapeutics by 27.5% during the fourth quarter. Fox Run Management L.L.C. now owns 22,050 shares of the biotechnology company’s stock valued at $399,000 after acquiring an additional 4,750 shares during the last quarter. Jane Street Group LLC boosted its stake in shares of Heron Therapeutics by 36.3% during the fourth quarter. Jane Street Group LLC now owns 18,806 shares of the biotechnology company’s stock valued at $340,000 after acquiring an additional 5,006 shares during the last quarter. Royce & Associates LP boosted its stake in shares of Heron Therapeutics by 17.4% during the third quarter. Royce & Associates LP now owns 67,500 shares of the biotechnology company’s stock valued at $1,090,000 after acquiring an additional 10,000 shares during the last quarter. Finally, Ellington Management Group LLC acquired a new stake in shares of Heron Therapeutics during the fourth quarter valued at $195,000.
ILLEGAL ACTIVITY NOTICE: “Heron Therapeutics (HRTX) Upgraded at ValuEngine” was first published by Ticker Report and is owned by of Ticker Report. If you are accessing this piece on another site, it was illegally copied and republished in violation of international copyright and trademark laws. The correct version of this piece can be read at https://www.tickerreport.com/banking-finance/3334299/heron-therapeutics-hrtx-upgraded-at-valuengine.html.
Heron Therapeutics Company Profile
Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.